<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217345</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001680</org_study_id>
    <nct_id>NCT02217345</nct_id>
  </id_info>
  <brief_title>Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of
      alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates
      of about 30% of individuals in the United States. A subset of these will develop progressive
      disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis
      and liver failure. NAFLD is expected to be the most common indication for liver
      transplantation by the year 2020. We hypothesize that growth hormone (GH) replacement will
      decrease intrahepatic lipid accumulation as quantified by 1H magnetic resonance spectroscopy
      (1H-MRS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic lipid content as measured by 1H-MRS</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>6 months</time_frame>
    <description>We will measure inflammatory markers such as high sensitivty C-reactive protein (hsCRP) (mg/L) and Il-6 (pg/mL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>Growth hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth hormone (somatropin) administered by daily injection at 0.3 mg daily for women and 0.2 mg daily for men given for the duration of the 6 month study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered by daily injection in this double blind study design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth hormone</intervention_name>
    <arm_group_label>Growth hormone</arm_group_label>
    <other_name>somatropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 18 - 65 yr

          2. NAFLD defined as demonstration of hepatic steatosis by imaging or biopsy in absence of
             significant alcohol consumption and other causes of hepatic steatosis. If liver
             imaging or biopsy has not been performed clinically, liver ultrasound will be
             performed as part of the screening visit.

        Exclusion Criteria:

          1. Serum creatinine &gt; 2 times the upper limit of normal

          2. History of cancer, except for non-melanoma skin cancers

          3. Active carpel tunnel syndrome

          4. Diabetes mellitus, defined as a hemoglobin A1C &gt;6.5 or use of any medications
             prescribed to treat hyperglycemia.

          5. Contraindications to magnetic resonance imaging (MRI).

          6. Pregnancy or desire to become pregnant. Participants of reproductive age must agree to
             use contraception.

          7. Breastfeeding

          8. Aspartate and aminotransferase levels &gt;5x upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Dichtel</last_name>
    <phone>617-724-3614</phone>
    <email>ldichtel@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Dichtel, MD</last_name>
      <phone>617-726-3870</phone>
      <email>LDichtel@partners.org</email>
    </contact>
    <investigator>
      <last_name>Karen K Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>August 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Director, Neuroendocrine Research Program in Women's Health</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

